It's J&J's top-selling product by far, generating nearly 10% of the company's total revenue in 2016. Midday Report: Wall Street Falters Amid Stimulus Impasse, Mixed Bank Results.

Suffice it to say that J&J has a big medical devices division that accounted for $26 billion of its sales last year, and a consumer unit that brought in $13.8 billion, about a third of that from over-the-counter drugs. J&J topped more than $80 billion in sales last year.

Roche boasts a diagnostics unit that produces some tests that work in tandem with drugs, but that’s far from all of its business. Johnson & Johnson shareholders have even more to like about 2017, with the dividend payout also at an all-time high. Johnson & Johnson shareholders have even more to like about 2017, with the dividend payout also at an all-time high. ... 12/31/2017. As a result, Pfizer sued J&J for alleged violation of antitrust laws. Multiple myeloma drug Darzalex should become a blockbuster in its first full year on the market in 2017. One thing is certain: No matter what happens with those drugs, J&J will again appear at the top of this list in 2020. J&J has been so aggressive about hanging on to Remicade sales in the face of biosims, in fact, that one of its putative rivals sued, alleging that its payer contracting violates antitrust rules. This year, unless J&J manages to win its appeal, Zytiga is set for a long downhill slide.

In November, J&J lost its bid to stop knockoffs from launching before its appeal to the Federal Circuit could be heard. Some observers thought that J&J overpaid for the Swiss drugmaker (including me). The company will continue to face competition for Remicade. The schizophrenia drug should make around $2.5 billion in 2017. Its immunology franchise, for one. Several other drugs in addition to Remicade experienced sales declines in 2017. Domestic sales increased 1.5%. But for years now, J&J’s pharma business has powered the conglomerate’s growth. The bigger deal, however, was Johnson & Johnson's buyout of Actelion for $30 billion, which closed in June. In other words, pharma accounted for the lion’s share of J&J’s absolute sales growth last year and just about half of its total sales. Stelara helped offset Remicade's sales drop to a large extent. Subscribe to FiercePharma to get industry news and updates delivered to your inbox. Please try again by refreshing your browser or contact us with details of your problem. 3 Speen Street, Suite 300, Framingham, MA 01701. exclude terms. Sign in. With 2017 drawing to a close, we now know the answer to that question: Pretty good. Every year, in recent memory at least, the company posts big gains for its prescription drug portfolio.

View and export this data going back to 1984.

See you at the top! Find out the revenue, expenses and profit or loss over the last fiscal year.

Every year, Johnson & Johnson far and away tops the list of drugmakers ranked by total revenue. And Zytiga faces an even bigger threat. The Ascent is The Motley Fool's new personal finance brand devoted to helping you live a richer life. J&J is one of the world's most valuable companies. A big question among Johnson & Johnson shareholders for 2017 was how autoimmune disease drug Remicade, would fare against biosimilar competition from Pfizer (NYSE:PFE). The company’s pulmonary hypertension drugs Opsumit, Tracleer and Uptravi together brought in almost $2.5 billion. Revenue is an extremely important metric when analyzing a company. Expect these same factors to be important for Johnson & Johnson in 2018 also.

Enclose phrases in quotes. 12/31/2016. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. This is also considered the "top-line" of the income statement. No doubt the company’s prescription drugs are valued at J&J. Johnson & Johnson’s total shareholder return for 2017 was more than 24%, exceeding our competitor composite, as well as exceeding most major indices which, I am proud to say, Johnson & Johnson has done over the last three-, MARCH 2018 TO OUR SHAREHOLDERS ALEX GORSKY Chairman and Chief Executive Officer $)"*3. The psoriasis and psoriatic arthritis drug is on track to generate sales approaching $4 billion this year. Revenues measure the total amount of value that a company brings in during a certain period. J&J’s anticoagulant Xarelto put in about the same amount—flat compared with 2017, partly thanks to stepped-up competition from Pfizer and Bristol-Myers Squibb’s Eliquis—while SGLT2 diabetes drug Invokana pitched in less than $1 billion as safety worries eroded its blockbuster sales. 37 on the 2018 Fortune 500 list of the largest United States corporations by total revenue. Stock Advisor launched in February of 2002. RELATED: As competition heats up, U.S. prices for Remicade and biosims slip. What can make up the difference? View JNJ financial statements in full. Johnson & Johnson is an American multinational corporation founded in 1886 that develops medical devices, pharmaceutical, and consumer packaged goods. The healthcare giant's share price is up close to 24% year to date. Compare JNJ With Other Stocks Largely as a result of this acquisition, J&J's medical device segment posted solid sales growth in 2017. RELATED: J&J chief Gorsky took a big pay hit in 2018 but still nabbed $20M. Still, my view is that 2018 will again be a solid year for J&J. But unless the courts force J&J to change its practices, its contracting approaches should help control sales losses to a manageable level. In depth view into Johnson & Johnson Revenue (TTM) including historical data from 1970, charts, stats and industry comps.

With less than two weeks remaining in 2017, Johnson & Johnson (NYSE:JNJ) is on track to have its second-best year of the century so far for stock performance. An error occurred. Then there’s Actelion, the new purchase J&J brought into the fold in 2017. Just last month, the company nabbed FDA approval for Spravato, an inhaled remedy for severe depression based on the party drug ketamine, and some analysts see that drug hitting $3 billion in annual sales down the line. Eliquis looks poised to continue grabbing share from Xarelto.

Let's conquer your financial goals together...faster. Market data powered by FactSet and Web Financial Group. Pharma, in fact, has been J&J’s growth engine through trouble for its medical devices business and a slowdown in consumer health. J&J rolled out a new prostate cancer drug, Erleada, last February, and analysts figure it can reach $1.3 billion in sales in a few years; the company posted data in January of this year that could put it in line for another approval. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. This deal was completed in February, and brought a lineup of cataract surgery, laser refractive surgery and consumer eye health products into J&J's fold to join the company's successful Acuvue contact lens business. The decline in the second quarter Johnson And Johnson's Revenue compares unfavorably to the Company's average Revenue growth of 2.2%. But J&J’s oncology business really revved up in 2018. Johnson & Johnson Common Stock (JNJ) Revenue EPS : Previous 3 Years Next 3 Years. Will Covid-19 Vaccine Race Leaders Pfizer, BioNTech Post Initial Phase 3 Data This Week? A company with efficient margins is able to turn revenues into the most net income.

JNJ Revenue second quarter 2020 Y/Y Growth Comment: Johnson And Johnson reported fall in Revenue in the second quarter by -10.83% to $ 18,336.00 millions, from the same quarter in 2019. J&J filed for approval in October for promising prostate cancer drug apalutamide. One could argue, however, that J&J doesn’t belong in first place in this annual ranking. This year could bring some big changes, though. Get the detailed quarterly/annual income statement for Johnson & Johnson (JNJ). Did Vaxart exaggerate Warp Speed role to enrich insiders. Back to JNJ Overview ©2020, EDGAR®Online, a division of Donnelley Financial Solutions. Here are the top three reasons. Pfizer, however, isn't a happy camper. J&J Pauses Coronavirus Vaccine Trial: ETFs That May Take a Hit, ‘The medical community has learnt a lot’ and are ‘better prepared’ for the next phase: doctor, Johnson & Johnson stock outperforms market despite losses on the day. Novartis sells contact lenses through its soon-to-be-spun-off subsidiary Alcon.

Report: Johnson & Johnson Coronavirus Vaccine Study Paused Due To Participant's Unexplained Illness, Copyright, Trademark and Patent Information. J&J’s overall revenue came in at $81.58 billion, up a little more than $4 billion over the $76.45 billion the conglomerate brought in the previous year. Johnson & Johnson - Get Report ... Revenue for the quarterly period was tabbed at $18.1 billion, the company said, just shy of the FactSet forecast of $18.26 billion. Johnson & Johnson annual net income for 2017 was $1.3B , a 92.14% decline from 2016. What’s fueling all of that? Returns as of 10/15/2020. A big chunk of J&J’s consumer sales come from over-the-counter drugs, a segment that also contributes to GlaxoSmithKline, Pfizer, Bayer and Sanofi’s top lines. Last year, for instance, J&J’s pharma business brought in $40.7 billion, an increase of almost $4.5 billion—or 12%—over 2017’s $36.26 billion. Roche reported CHF 56.8 billion in 2018 sales, 44 billion of that in its pharma division—more than J&J’s pharma business brought in. However, Actelion was expected to give a shot in the arm to J&J's pharmaceutical segment -- and it did.

Cumulative Growth of a $10,000 Investment in Stock Advisor, Why 2017 Was a Year to Remember for Johnson & Johnson @themotleyfool #stocks $JNJ $PFE $ABT, Got $500?

Johnson & Johnson's strongest sales growth this year, however, came from its oncology lineup. But big drugmakers are messy. (Johnson & Johnson). Psoriasis and psoriatic arthritis drug Stelara ginned up $5.2 billion last year, a 28% year-over-year sales hike, and psoriasis newcomer Tremfya brought in $544 million, up from just $63 million in 2017. Overall, cancer drugs brought in almost $10 billion for J&J. At the same time, Stelara, Invega Sustenna, Darzalex, and Imbruvica should enjoy sustained momentum. Even with the sales decline this year, the drug will still represent close to 9% of total revenue. Operational sales results increased 3.3% and the negative impact of currency was 2.3%. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. All rights reserved. Thanks to the Actelion buyout, Johnson & Johnson now has a solid pulmonary hypertension franchise. The good news, though, was that strong momentum continued for several key drugs.

Johnson & Johnson balance sheet, income statement, cash flow, earnings & estimates, ratio and margins. Animal health pitches in at Merck, Eli Lilly (for now) and Boehringer Ingelheim, among others. Will Earnings Reports Drive Shares This Earnings Season? 'Halftime Report Traders' Share Their Thoughts On Target, Johnson & Johnson And More. For advanced charting, view our full-featured. And that pharma business has outclassed most of its Big Pharma peers growth-wise, too. Imbruvica, which won two new FDA approvals this year for treating marginal zone lymphoma and chronic graft versus host disease, is on pace to make close to $2 billion in 2017. Remicade remains a very important component of Johnson & Johnson's lineup. Novartis totted up $44.8 billion between its innovative medicines and generic-and-biosimilars group, Sandoz—also more than J&J’s pharma group. J&J stock is at an all-time high. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. And those newer drugs delivered at the same time aging stalwart Remicade stubbornly clung to market share to pitch in $13 billion despite biosimilar competition.